Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error screen, replacing the study record content and navigation. The previous study details and related sections are no longer visible on this page.
    Difference
    19%
    Check dated 2026-09-20T22:16:33.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page now displays a new revision label (v3.6.6) replacing the previous v3.6.5, indicating a new build of the site. This reflects a maintenance/version update rather than substantive changes to study content or user-facing features.
    Difference
    0.1%
    Check dated 2026-08-30T15:42:10.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.5, indicating an updated site deployment. The previous Revision: v3.6.4 label has been superseded.
    Difference
    0.1%
    Check dated 2026-08-09T00:34:52.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    Removed the reference to the 2012 NEJM article Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. This background citation supported contextual information but is not part of the study's design, results, or eligibility details.
    Difference
    0.1%
    Check dated 2026-08-01T22:55:40.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The page shows a new revision tag v3.6.4 replacing the previous v3.6.3, indicating a minor patch or update to the page or system without visible content changes.
    Difference
    0.1%
    Check dated 2026-07-25T16:59:28.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    The page’s revision indicator was updated to v3.6.3, indicating a minor site update. This does not modify the study details or related data.
    Difference
    0.1%
    Check dated 2026-07-04T04:25:38.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.